EWA
IKT icon

EverSource Wealth Advisors’s Inhibikase Therapeutics IKT Stock Holding History

EverSource Wealth Advisors’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$357 Buy
213
+209
+5,225% +$371 ﹤0.01% 4115
2025
Q4 		$8 Buy
+4
New +$6 ﹤0.01% 4252

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EverSource Wealth Advisors's IKT Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Inhibikase Therapeutics (IKT) stake by 5,225% in Q1 2026, buying an estimated $371 and bringing the position to 213 shares worth $357. The position accounts for ﹤0.01% of the portfolio, ranked #4115.

EverSource Wealth Advisors first reported a position in IKT in Q4 2025 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • EverSource Wealth Advisors held 213 shares of Inhibikase Therapeutics worth $357 as of Q1 2026.
  • EverSource Wealth Advisors bought 209 Inhibikase Therapeutics shares in Q1 2026, an estimated $371.
  • Inhibikase Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #4115 holding.
  • EverSource Wealth Advisors first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.